Adalvo is very proud to announce that our dossier for Pregabalin ER tablets has been submitted successfully.
Pregabalin is a backbone medication indicated in the treatment of Neuropathic pain. Having a unique formulation, the benefit of this product is increased patient adherence to the therapy through the reduction of the daily administration requirements.
Pregabalin annual sales is $2.3bn, according to 2021 IQVIA.
Based on this positive outcome, our goal is to offer the first once-daily Pregabalin formulation, available for patients in Europe, if approved by health authorities.
We are very proud to have achieved this extraordinary milestone, having completed our own successful Phase III study with a patient population of over 450 patients, and more than 20 clinical sites, which has enabled Adalvo to offer Pregabalin Extended-Release to patients in Europe and across the world.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
aitor.alferez@adalvo.com – South Europe & Israel
giorgio.catolfi@adalvo.com - LATAM
jose.rendueles@adalvo.com- North Europe, APAC and MENA,
margarida.neves@adalvo.com – Brazil
paulo.rodriguez@adalvo.com – LATAM (Exc. Brazil)
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Pregabalin which is subject to patent protection is currently not offered or made available in countries where patents are in force.